In bid to lower ARIA-E, Eli Lilly tries a different dosing regimen for its Alzheimer's drug
Eli Lilly presented new data illustrating how a different dosing regimen of its Alzheimer’s drug reduced the frequency of brain swelling.
The results could help …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
